China-based Zhejiang Pushkang Biotechnology Co., Ltd, a leading centrifugal microfluidic platform company, has reportedly raised over RMB 100 million (USD 13.7 million) in a Series C+ financing round. The round was led by Oct. Capital, with participation from Momentum Venture and Chang An Hui Tong, alongside returning investor Yinglian Health Industry Equity Investment Fund. The proceeds will be used to accelerate the company’s product pipeline, focusing on critical and severe as well as chronic disease management, and to enhance its overseas marketing layout for its centrifugal microfluidic platform products.
Company Background and Product Portfolio
Founded in 2014, Pushkang Biotechnology is known for its comprehensive point-of-care testing (POCT) products, which cover coagulation, biochemistry, luminescence, molecules, and more. The company’s products are widely applied across various settings, including laboratories, emergency departments, and on-site departments. Its desktop high-flux instrument is designed for high-throughput testing, while its portable instrument is highly automated and convenient, featuring freeze-drying reagent packaging. These portable devices are ideal for use in community hospitals, clinics, and pharmacies.
Partnerships and Future Outlook
Pushkang Biotechnology has established strategic partnerships with companies such as Autobio Diagnostics and Huadong Medicine to further expand its market reach and enhance its product offerings. The recent Series C+ financing round underscores the company’s commitment to innovation and its goal of becoming a leading player in the global microfluidic platform market. The funds will support the development of new products and the expansion of its overseas market presence.-Fineline Info & Tech
